Intangible Assets

12 Months Ended

Dec. 31, 2014

Goodwill And Intangible Assets Disclosure [Abstract]

NOTE 7 – INTANGIBLE ASSETS

Intangible assets for IPR&D consist of two clinical product candidates from our acquisition of Ceregene. IPR&D is an intangible asset classified as indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. If the project is abandoned, the IPR&D will be expensed at the time such determination is made.

The carrying values of these intangibles assets are as follows (in thousands):

	Year ended December 31,
	2014		2013
CERE-110 for the treatment of Alzheimer's disease	$	1,640	$	1,640
CERE-120 for the treatment of Parkinson's disease		230		230
Total identifiable intangible assets	$	1,870	$	1,870